NR4A1 and neoplasm: We first built a base model that included known prognostic variables: pCR status, treatment group (weekly paclitaxel plus trastuzumab plus lapatinib, weekly paclitaxel plus lapatinib, or weekly paclitaxel plus trastuzumab, where the latter is the reference group), hormone receptor status, clinical stage, and PAM50 intrinsic tumor subtype (HER2-enriched vs other subtypes) (model 1).